GlassScriptPhysician profile
James R Bond
NPI 1659375616
$3,653.77
in general payments reported to CMS, 2019-2025
31 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $191 · 2021: $45.11 · 2022: $101 · 2023: $524 · 2024: $1,237 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,668 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.61 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.76 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $460.22 | 2019-2025 | Rinvoq |
| Arcutis Biotherapeutics, INC. | $372.05 | 2023-2025 | Zoryve |
| Pfizer INC. | $215.85 | 2019-2025 | |
| Strata Skin Sciences, INC. | $212.64 | 2024 | Xtrac |
| Incyte Corporation | $179.36 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $175.92 | 2019-2025 | |
| Ucb, INC. | $162.88 | 2019-2025 | Bimzelx |
| Shockwave Medical, INC | $162.21 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $159.91 | 2019-2024 | Taltz, Olumiant |
| Dermavant Sciences, INC. | $132.07 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $104.25 | 2023-2025 | Sotyktu |
| Organon LLC | $93.22 | 2025 | Hadlima, Vtama |
| Janssen Biotech, INC. | $90.05 | 2022-2024 | Tremfya, Stelara, Simponi |
| Leo Pharma INC. | $88.87 | 2019-2025 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $70.30 | 2024-2025 | |
| Galderma Laboratories, L.P. | $65.80 | 2019-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $49.77 | 2020-2021 | |
| Encore Dermatology INC. | $48.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.41 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.72 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $38.22 | 2019-2025 | Libtayo |
| Verrica Pharmaceuticals INC. | $36.47 | 2025 | Ycanth |
| Genzyme Corporation | $30.52 | 2024 | |
| Access Pro Medical, LLC | $24.89 | 2023 | Matriderm |
| Promius Pharma LLC | $24.31 | 2019 | |
| Silk Road Medical, INC. | $22.46 | 2021 | |
| Glaxosmithkline, LLC. | $18.52 | 2022 | |
| Medtronic, INC. | $17.95 | 2025 | Venaseal |
| Dusa Pharmaceuticals, INC. | $17.49 | 2019 | |
| Aclaris Therapeutics, INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.